Development of High Throughput Assays for the Hepatitis C Virus NS2 Protease
丙型肝炎病毒 NS2 蛋白酶高通量检测方法的开发
基本信息
- 批准号:8293899
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-02-15 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AreaBiological AssayBiologyBlood-Borne PathogensCalpainCell CountChemicalsChronicCirrhosisDevelopmentDimethyl SulfoxideDiseaseEngineeringEnvironmentExcisionFlowchartsFutureGelGenerationsGenomicsGenotypeGoalsGrantHIV-1HepaticHepatitis CHepatitis C virusHumanIndividualInfectionInflammationLaboratoriesLaboratory ResearchLibrariesLife Cycle StagesLiverLiver diseasesMeasurementMethodsMonitorNaturePatientsPeptide HydrolasesPharmacotherapyPoisonPolymerasePolyproteinsPrimary carcinoma of the liver cellsPropertyProtease InhibitorProteinsRNA replicationReagentRepliconResearchResistanceRoleScreening procedureSeriesSignal TransductionSpecificityStagingTestingTherapeuticTimeToxic effectTransactivationTriageUnited States National Institutes of HealthVaccinesValidationViralViral Drug ResistanceViral GenomeViral ProteinsVirusVirus DiseasesVirus Replicationassay developmentbasehigh throughput screeninginhibitor/antagonistmethod developmentminiaturizemutantpreventprogramsprotein functionresearch studysmall moleculetat Proteintherapeutic developmenttooltransmission processviral RNA
项目摘要
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection afflicts approximately 170 million people worldwide and chronic virus replication in these individuals is a significant cause of liver inflammation, cirrhosis, hepatocellular carcinoma, and a host of extra-hepatic disease states. No vaccine exists to prevent transmission of this blood borne pathogen, and the current non-specific drug therapy used to treat patients is of limited efficacy for the mos common HCV genotypes. Although progress has been made in the last decade in the development of specific small molecule inhibitors targeting a number of viral proteins, the error prone nature of HCV RNA replication suggests resistance to these inhibitors will develop. A cocktail-based therapeutic approach using multiple specific inhibitors targeting distinct aspects of the HCV life cycle is therefore a prudent strategy for future therapeutics, and this approach requires the development of numerous specific inhibitors with unique mechanisms of action. Despite an essential role in the virus life cycle, the viral NS2 protease has seen surprisingly litle activity as an anti-viral target. NS2 is a papain-like cysteine protease that catalyzes the auto-catalytic cleavage of the NS2/NS3 junction in the viral polyprotein, and this cleavage is essential
for productive infections. Using a series of engineered autonomously replicating HCV replicons, we have developed a potential screen to identify compounds that disrupt viral replication in a manner dependent on NS2 activity. Although preliminary results suggest the large format version of this assay can identify NS2 inhibitors, considerable effort will be required before this
assay can be moved into a high content screening environment. This application is directed towards announcement PA-10-213, a program specifically geared towards assay development for eventual access to the NIH MLPCN screening center program. The overall goal of this proposed project is to develop our assay for NS2 function into an assay appropriate for high throughput small molecule screening and develop appropriate counter and secondary screens to maximize the impact of future screening efforts. To this end we have proposed a series of logical experiments in three specific aims to miniaturize and validate our assay, develop appropriate counter screens that fit into a logical compound triaging plan, and provide a context in which tool compounds that result from our screen might be used to understand HCV biology.
PUBLIC HEALTH RELEVANCE: This project involved the optimization of research tools for the analysis of the hepatitis C virus NS2 protease and the application of these tools to develop high throughput screens for chemical inhibitors of this protease. The NS2 protein is essential for hepatitis C replication, but poorly understood, and inhibitor compound may be useful in determining the functions of this protein as well as of benefit as future human therapeutics.
描述(由申请人提供):丙型肝炎病毒(HCV)感染困扰着全世界约 1.7 亿人,这些人体内的慢性病毒复制是肝脏炎症、肝硬化、肝细胞癌和许多肝外疾病状态的重要原因。目前还没有疫苗可以预防这种血源性病原体的传播,而且目前用于治疗患者的非特异性药物疗法对于最常见的 HCV 基因型的疗效有限。尽管过去十年在针对多种病毒蛋白的特定小分子抑制剂的开发方面取得了进展,但 HCV RNA 复制容易出错的性质表明对这些抑制剂的耐药性将会出现。因此,使用多种特异性抑制剂针对 HCV 生命周期不同方面的基于鸡尾酒的治疗方法是未来治疗的谨慎策略,并且该方法需要开发大量具有独特作用机制的特异性抑制剂。尽管病毒 NS2 蛋白酶在病毒生命周期中发挥着重要作用,但其作为抗病毒靶标的活性却令人惊讶地少。 NS2是一种类似木瓜蛋白酶的半胱氨酸蛋白酶,催化病毒多蛋白中NS2/NS3连接处的自催化裂解,并且这种裂解是必需的
用于生产性感染。使用一系列工程化的自主复制 HCV 复制子,我们开发了一种潜在的筛选方法来识别以依赖 NS2 活性的方式破坏病毒复制的化合物。尽管初步结果表明该检测的大幅面版本可以识别 NS2 抑制剂,但在此之前还需要付出相当大的努力
测定可以转移到高内涵筛选环境中。该申请针对公告 PA-10-213,该计划专门针对最终访问 NIH MLPCN 筛选中心计划的分析开发。该拟议项目的总体目标是将我们的 NS2 功能测定开发为适合高通量小分子筛选的测定,并开发适当的计数器和二次筛选,以最大限度地提高未来筛选工作的影响。为此,我们针对三个具体目标提出了一系列逻辑实验,以小型化和验证我们的测定,开发适合逻辑化合物分类计划的适当计数器屏幕,并提供一个背景,在该背景下,我们的屏幕产生的工具化合物可用于理解 HCV 生物学。
公共健康相关性:该项目涉及丙型肝炎病毒 NS2 蛋白酶分析研究工具的优化,以及应用这些工具开发该蛋白酶化学抑制剂的高通量筛选。 NS2 蛋白对于丙型肝炎复制至关重要,但人们对其知之甚少,抑制剂化合物可能可用于确定该蛋白的功能以及有益于未来的人类治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY TELLINGHUISEN其他文献
TIMOTHY TELLINGHUISEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY TELLINGHUISEN', 18)}}的其他基金
Hepatitis C virus polyprotein processing efficiency regulates infectious virus production
丙型肝炎病毒多蛋白加工效率调节感染性病毒的产生
- 批准号:
9222690 - 财政年份:2016
- 资助金额:
$ 34.65万 - 项目类别:
Development of High Throughput Assays for the Hepatitis C Virus NS2 Protease
丙型肝炎病毒 NS2 蛋白酶高通量检测方法的开发
- 批准号:
8424200 - 财政年份:2012
- 资助金额:
$ 34.65万 - 项目类别:
Development of High Throughput Assays for the Hepatitis C Virus NS2 Protease
丙型肝炎病毒 NS2 蛋白酶高通量检测方法的开发
- 批准号:
8602829 - 财政年份:2012
- 资助金额:
$ 34.65万 - 项目类别:
CARD14 is essential for hepatitis C virus replication and activation of NFKB
CARD14 对于丙型肝炎病毒复制和 NFKB 激活至关重要
- 批准号:
8179816 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
CARD14 is essential for hepatitis C virus replication and activation of NFKB
CARD14 对于丙型肝炎病毒复制和 NFKB 激活至关重要
- 批准号:
8528571 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
CARD14 is essential for hepatitis C virus replication and activation of NFKB
CARD14 对于丙型肝炎病毒复制和 NFKB 激活至关重要
- 批准号:
8335371 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
CARD14 is essential for hepatitis C virus replication and activation of NFKB
CARD14 对于丙型肝炎病毒复制和 NFKB 激活至关重要
- 批准号:
8882406 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
CARD14 is essential for hepatitis C virus replication and activation of NFKB
CARD14 对于丙型肝炎病毒复制和 NFKB 激活至关重要
- 批准号:
8699760 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 34.65万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 34.65万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 34.65万 - 项目类别:
Postdoctoral Fellowships